The nation of Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (£272m) over five years due to the United States' demand for confidential data.
This move became public following a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman has since stated that the US was demanding access to biological samples for research and profit while refused to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for continued dialogue to reach a deal agreeable to all parties so the nation's critical HIV programme can continue.
Broader Context
This rejection follows a similar case in Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
According to reports, Sixteen nations in Africa have to date signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," he stated.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the resulting innovations would be available to our people should a future health crisis arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending structures already set up via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system designed to deal with future global health emergencies.
"This system is intended to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent co-operation might be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it recognised the official position, but suggested that negotiations must proceed given that much of the country's HIV programmes were funded by foreign aid.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group added.
The situation emphasises the ongoing tensions between accepting crucial foreign assistance and protecting a country's data in an increasingly interconnected world.